Navigation Links
VIA Pharmaceuticals Complies With NASDAQ Rule
Date:3/28/2008

A approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to obtain and protect our intellectual property related to

our product candidates;

-- our potential for future growth and the development of our product

pipeline;

-- our ability to form and maintain collaborative relationships to develop

and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under Item IA "Risk Factors" in our Annual

Report on Form 10-K for the fiscal year ended December 31, 2007 on file

with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
2. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
3. SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
4. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
5. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
6. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
7. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
8. SGX Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
9. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
10. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
11. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... Outstanding Issues (LOI) from the European Medicines Agency,s Committee ... NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained release ... being evaluated for weight loss. The key ... adequately addressed by the Company based in part on ...
(Date:7/30/2014)... , July 30, 2014  RXi ... a biotechnology company focused on discovering, developing ... medical needs using RNA-targeted technologies, today announced ... with RXI-109, for the reduction of recurrence ... surgery, has been initiated. Logo ...
(Date:7/30/2014)... 2014 Immunology Summit-2014 ... Principle Investigators, scientists in the field, which includes ... at Case Western Reserve University School of Medicine, ... on “The effects of recombinant human IL-6 ... metalloproteinase-9”. Arya Biragyn, a Senior investigator at National ...
(Date:7/29/2014)... The advanced optical methods and applications for ... a revolution in the neurosciences were the inspiration behind ... SPIE, the international society for optics and photonics ... of the BRAIN Initiative in the United States, and ... vision for and provide examples of the impact that ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4
... FRANCISCO , Jan. 13 Today, endpoint ( ... users to design and deploy clinical trial IRT systems in ... Leveraging a background of more than 12 years designing Integrated ... designed PULSE to balance speed of deployment with flawless quality. ...
... ROCHESTER, N.Y. , Jan. 12 After a decade of ... decelerated and may have even fallen when adjusted for inflation.  That is ... the American Medical Association .   , "The era of rapid expansion ... Ray Dorsey , M.D. , a neurologist at the ...
... , ... Institute announces twenty-four exhibitors to showcase new products at the 17th Molecular Medicine Tri-Conference, ... Molecular Medicine Tri-Conference is the predominant event on the west coast focused on integrating ... ...
Cached Biology Technology:endpoint Introduces First Fully Configurable IRT System 2Study: Era of Rapid Growth in Biomedical Research Over 2Study: Era of Rapid Growth in Biomedical Research Over 3Study: Era of Rapid Growth in Biomedical Research Over 4Study: Era of Rapid Growth in Biomedical Research Over 5Study: Era of Rapid Growth in Biomedical Research Over 6A Host of New Products to be Showcased at 2010 Molecular Medicine Tri-Conference 2A Host of New Products to be Showcased at 2010 Molecular Medicine Tri-Conference 3A Host of New Products to be Showcased at 2010 Molecular Medicine Tri-Conference 4
(Date:7/30/2014)... Monash University Professor Steven Chown has been awarded ... Medal for Excellence in Antarctic Research. , SCAR, ... coordinates high quality international scientific research in the ... Antarctic region in the Earth system. The organisation ... Antarctic Treaty System, responsible for governing the region. ...
(Date:7/30/2014)... for spinal cord injury (SCI), traumatic brain injury (TBI) ... deal has been learned over the past 30 years ... that regulate axon growth, but this large body of ... Prof. Lemmon and his team from University of Miami ... causes, but a consensus is emerging that one contributing ...
(Date:7/30/2014)... , July 30, 2014 The Nano-Bio ... United States Air Force Research Laboratory (AFRL), has ... Binghamton University to develop electronics ... (HPM). The $425,000 project, with contributions from the ... i3 Electronics, Inc. ( Endicott, N.Y. ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... $50 million to a multi-institution collaborative headquartered at the ... cyberinfrastructure for the biological sciences. The renewal ... the Texas Advanced Computing Center (TACC) at the University ... New York, and University of North Carolina Wilmington (UNCW), ...
... Researchers have discovered why multiple myeloma, a difficult to cure ... effective treatment that can keep the disease at bay for ... colleagues at Princess Margaret Hospital in Toronto, researchers from Mayo ... in Phoenix were part of the team that conducted the ...
... NEW YORK , Sept. 18, 2013 ... research report is available in its catalogue: ... Global Biometrics Market ... the Market Grow Manifold,This study analyzes the ...
Cached Biology News:$50 million NSF grant to advance cyberinfrastructure for big data in life sciences 2$50 million NSF grant to advance cyberinfrastructure for big data in life sciences 3$50 million NSF grant to advance cyberinfrastructure for big data in life sciences 4Research team uncovers root cause of multiple myeloma relapse 2Emerging Opportunities in Global Biometrics Market 2Emerging Opportunities in Global Biometrics Market 3Emerging Opportunities in Global Biometrics Market 4Emerging Opportunities in Global Biometrics Market 5
Request Info...
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer Pre-designed siRNAs, which ...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
Biology Products: